tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Quantum BioPharma submits Lucid-21-302 to ILAP program in the UK

Quantum BioPharma announces through its subsidiary, Huge Biopharma Australia, the submission of its patented candidate breakthrough drug, Lucid-21-302, to the Innovative Licensing and Access Pathway Passport program in the United Kingdom. The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1